Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic ...
Overactive bladder appears in 62.0% and 28.6% of patients with and without fibromyalgia, respectively. HealthDay News — Overactive bladder (OAB) is prevalent among women with fibromyalgia (FM) and is ...
Effects of Angelica archangelica Extract on Overactive Bladder: A Pilot Randomized Controlled Trial.
Overactive bladder (OAB) is a prevalent syndrome affecting quality of life (QoL) in 10.8% of men and 12.8% of women in Europe, impacting various aspects of daily functioning. Conventional treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback